Edition:
United States

Pfizer Inc (PFE)

PFE on New York Consolidated

41.95USD
24 May 2019
Change (% chg)

$0.03 (+0.07%)
Prev Close
$41.92
Open
$42.06
Day's High
$42.31
Day's Low
$41.87
Volume
14,595,227
Avg. Vol
24,382,205
52-wk High
$46.47
52-wk Low
$35.32

Latest Key Developments (Source: Significant Developments)

Pfizer's Lyrica Fails to Meet Main Goal in Late-stage Epilepsy Study
Friday, 24 May 2019 04:00pm EDT 

May 24 (Reuters) - Pfizer Inc ::PFIZER ANNOUNCES TOP-LINE RESULTS FROM PHASE 3 TRIAL OF LYRICA® (PREGABALIN) IN PRIMARY GENERALIZED TONIC-CLONIC SEIZURES.PFIZER INC - TREATMENT WITH LYRICA DID NOT RESULT IN A STATISTICALLY SIGNIFICANT REDUCTION IN SEIZURE FREQUENCY VERSUS PLACEBO.PFIZER INC - STUDY DID NOT MEET ITS PRIMARY ENDPOINT.PFIZER INC - SAFETY PROFILE OBSERVED IN PHASE 3 STUDY WAS COMPARABLE TO KNOWN PROFILE OF LYRICA IN PRIOR EPILEPSY STUDIES.  Full Article

EMA Recommends Restrictions In Use Of Xeljanz While It Reviews Risk Of Blood Clots In Lungs
Friday, 17 May 2019 07:05am EDT 

May 17 (Reuters) - European Medicines Agency::PRAC RECOMMENDING DOCTORS NOT PRESCRIBE 10 MG TWICE DAILY DOSE OF XELJANZ (TOFACITINIB)IN PATIENTS AT HIGH RISK OF BLOOD CLOTS IN LUNGS.PRAC’S RECOMMENDATION ON XELJANZ FOLLOWS RESULTS FROM ONGOING STUDY IN PATIENTS WITH RHEUMATOID ARTHRITIS.NEW RECOMMENDATIONS TEMPORARY, FOLLOW PREVIOUS PRAC ADVICE NOT TO EXCEED RECOMMENDED 5 MG TWICE DAILY DOSE WHEN TREATING RHEUMATOID ARTHRITIS.  Full Article

FDA Approves First Anticoagulant For Pediatric Patients
Thursday, 16 May 2019 01:35pm EDT 

May 16 (Reuters) - FDA::FDA APPROVES FIRST ANTICOAGULANT (BLOOD THINNER) FOR PEDIATRIC PATIENTS TO TREAT POTENTIALLY LIFE-THREATENING BLOOD CLOTS.FDA- APPROVED FRAGMIN INJECTION, FOR SUBCUTANEOUS USE, TO REDUCE RECURRENCE OF SYMPTOMATIC VENOUS THROMBOEMBOLISM IN PEDIATRIC PATIENTS 1 MONTH OF AGE & OLDER.  Full Article

Pfizer Says FDA Approves Bavencio Plus Inlyta For Patients With Advanced Renal Cell Carcinoma
Tuesday, 14 May 2019 07:44pm EDT 

May 14 (Reuters) - Pfizer Inc ::FDA APPROVES BAVENCIO® (AVELUMAB) PLUS INLYTA® (AXITINIB) COMBINATION FOR PATIENTS WITH ADVANCED RENAL CELL CARCINOMA.  Full Article

Pfizer Hosts Annual Meeting Of Shareholders, Declares 36-Cent Q2 2019 Dividend
Thursday, 25 Apr 2019 11:17am EDT 

April 25 (Reuters) - Pfizer Inc ::PFIZER HOSTS ANNUAL MEETING OF SHAREHOLDERS.PFIZER INC - DECLARES 36-CENT SECOND-QUARTER 2019 DIVIDEND.PFIZER - PRELIMINARY RESULTS FROM ANNUAL MEETING OF SHAREHOLDERS HELD INDICATE THAT CO'S 11 DIRECTOR NOMINEES WERE RE-ELECTED TO ONE-YEAR TERMS.PFIZER INC - IN OTHER VOTING, SHAREHOLDER PROPOSALS WERE NOT APPROVED AT MEET.  Full Article

FDA Approves Merck's Keytruda In Combination With Inlyta As First-Line Treatment For Advanced Renal Cell Carcinoma
Monday, 22 Apr 2019 06:45am EDT 

April 22 (Reuters) - Merck & Co Inc ::FDA APPROVES MERCK’S KEYTRUDA® (PEMBROLIZUMAB) IN COMBINATION WITH INLYTA® (AXITINIB) AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC).MERCK - FDA APPROVES KEYTRUDA (PEMBROLIZUMAB) IN COMBINATION WITH INLYTA AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED RENAL CELL CARCINOMA.  Full Article

Pfizer Inc Says Tanezumab 5 Mg Treatment Arm Met Two Of Three Co-Primary Efficacy Endpoints
Thursday, 18 Apr 2019 05:05pm EDT 

April 18 (Reuters) - Pfizer Inc ::PFIZER AND LILLY ANNOUNCE TOP-LINE RESULTS FROM LONG-TERM PHASE 3 STUDY OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS.PFIZER INC - TANEZUMAB 5 MG TREATMENT ARM MET TWO OF THREE CO-PRIMARY EFFICACY ENDPOINTS.PFIZER - PATIENTS WHO GOT TANEZUMAB 2.5 MG DID NOT EXPERIENCE STATISTICALLY SIGNIFICANT IMPROVEMENT IN PAIN, PHYSICAL FUNCTION.PFIZER INC - THERE WERE 10 DEATHS IN STUDY.PFIZER - PATIENTS ON TANEZUMAB 2.5 MG DID NOT EXPERIENCE STATISTICALLY SIGNIFICANT IMPROVEMENT IN PATIENTS' OVERALL ASSESSMENT OF OA AT 16 WEEKS VERSUS NSAIDS.PFIZER INC - DISCONTINUATIONS DUE TO ADVERSE EVENTS WERE HIGHER AMONG THOSE RECEIVING TANEZUMAB COMPARED TO NSAIDS DURING 56-WEEK TREATMENT PERIOD.PFIZER INC - NINE DEATHS IN STUDY OCCURRED IN TANEZUMAB TREATMENT ARMS AND ONE DEATH IN NSAID TREATMENT ARM.PFIZER INC - NONE OF THE DEATHS IN THE STUDY WERE CONSIDERED TREATMENT-RELATED.  Full Article

Novitium Pharma Launches Thiothixene Capsules USP 1Mg, 2Mg, 5Mg, 10Mg
Tuesday, 16 Apr 2019 12:00pm EDT 

April 16 (Reuters) - Novitium Pharma LLC::NOVITIUM PHARMA LAUNCHES THIOTHIXENE CAPSULES USP 1MG, 2MG, 5MG, 10MG.NOVITIUM PHARMA - GOT FDA APPROVAL OF ITS MARKETING APPLICATION FOR THIOTHIXENE CAPSULES USP WHICH IS A THERAPEUTIC EQUIVALENT TO PFIZER'S NAVANE CAPSULES.  Full Article

Pfizer Announces Presentation Of Data From A Phase 2 Study Of Its 20-Valent Pneumococcal Conjugate Vaccine Candidate
Saturday, 13 Apr 2019 04:00am EDT 

April 13 (Reuters) - Pfizer Inc ::PFIZER ANNOUNCES PRESENTATION OF DATA FROM A PHASE 2 STUDY OF ITS 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE CANDIDATE BEING INVESTIGATED FOR THE PREVENTION OF INVASIVE DISEASE AND PNEUMONIA IN ADULTS AGED 18 YEARS AND OLDER.PFIZER - BIOLOGICS LICENSE APPLICATION IS EXPECTED TO BE SUBMITTED TO U.S. FDA BY END OF 2020, SUBJECT TO SUCCESSFUL COMPLETION OF PHASE 3 STUDIES.  Full Article

Cortexyme Inc Files For IPO Of Up To $86.25 Million
Friday, 12 Apr 2019 05:38pm EDT 

April 12 (Reuters) - Pfizer Inc ::CORTEXYME, INC FILES FOR IPO OF UP TO $86.25 MILLION - SEC FILING.CORTEXYME - APPLIED TO LIST OUR COMMON STOCK ON THE NASDAQ GLOBAL MARKET UNDER THE SYMBOL “CRTX”.CORTEXYME INC SAYS BOFA MERRILL LYNCH, CREDIT SUISSE, CANACCORD GENUITY AND JMP SECURITIES ARE UNDERWRITERS TO THE IPO.CORTEXYME INC SAYS ENTITIES AFFILIATED WITH PFIZER INC BENEFICIALLY OWNED 14.71 PERCENT OF COMMON SHARES PRIOR TO OFFERING.CORTEXYME INC SAYS TAKEDA VENTURES INC BENEFICIALLY OWNED 12.32 PERCENT OF COMMON SHARES PRIOR TO OFFERING.CORTEXYME INC - PROPOSED IPO PRICE IS AN ESTIMATE SOLELY FOR CALCULATING SEC REGISTRATION FEE.  Full Article